it appears the question of efficacy for SB is nearly confirmed by fda this month. so the next market risk is pipeline of new platforms, which is robust. if you believe in those platforms - than the only question is which (USA) Pharma company is the natural acquirer. and more importantly for shareholders: is it a strategic or economic multiple paid. I believe the terminal value is 3-5 aud per share in the next 5 years.
it appears the question of efficacy for SB is nearly confirmed...
-
- There are more pages in this discussion • 5,951 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.3¢ |
Change
-0.013(3.73%) |
Mkt cap ! $586.1M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 33.8¢ | 31.5¢ | $1.686M | 5.177M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 622684 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 313869 | 32 |
View Market Depth
| Last trade - 15.47pm 12/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |